# A biochemical screening platform to target chromatin states using condensates as a tool

## TL;DR

This paper introduces a new drug discovery platform that uses chromatin condensates to target dysfunctional chromatin states more specifically and reduce off-target effects.

## Contribution

A novel screening platform that targets chromatin states via phase-separated condensates, enabling specific modulation of multivalent interactions.

## Key findings

- Chromatin contexts can be recreated as phase-separated condensates with distinct biochemical and biophysical properties.
- The platform identifies small molecules that modulate chromatin states based on their specific chromatin context.
- This approach may reduce off-target effects and improve translation into human therapies.

## Abstract

Chromatin states define cell fates and consequently dysfunctional chromatin states drive disease. Conventional approaches to target dysfunctional chromatin states typically rely on targeting a defined, structured binding pocket of a specific chromatin protein. However, drugs developed from targeting single chromatin proteins have often failed in the clinic due to toxicity from broad non-specific effects on the genome. Substantial previous work has indicated that the function of a given chromatin state is encoded in the context-dependent protein-protein interactions (PPIs) between the Intrinsically disordered regions (IDRs) and folded domains of the multiple constituents. Currently, there are no drug discovery approaches that target the complex multivalent protein interactions within a given dysfunctional chromatin state. Therefore, new methods are required to target chromatin within specific conformational contexts for better translation into humans. Prior discoveries from our group and others have shown that chromatin intrinsically forms condensates through weak, yet specific, multivalent interactions between itself and other components. Using this intrinsic property of chromatin, we have developed a new screening method to address this technology gap and identify modulators of dysfunctional chromatin states for drug discovery. Here, we show that we can recreate different chromatin contexts as phase-separated condensates that have distinct biochemical and biophysical properties. Furthermore, we have scaled the technology into a screening platform and identify small molecules that modulate chromatin states specifically based on their chromatin context. We anticipate that such specific targeting of a disease driving chromatin assembly would reduce off-target effects, translate better into humans and open a new landscape of therapeutic possibilities for targeting complex, multivalent interactions.